Some workers are willing to trade vacation days or go back to the office in exchange for weight-loss drug coverage by their ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Compounded weight-loss medications such as those promoted in the Hims & Hers commercial aren’t approved by the Food and Drug ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

On the charts, today's pop has NVO on track to snap a three-day losing streak. The stock still hasn't recovered from its ...

the key ingredient in Wegovy and Ozempic, will go into its full-year results on Wednesday more bruised than it has ever been since its GLP-1 diabetes medications became popularized as weight loss ...

A new study examines how cost, side effects and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Weight-loss drugs will be ... marketed under the brand name Wegovy, and tirzepatide, sold as Mounjaro. Semaglutide is also used in the type 2 diabetes treatment Ozempic. Both Wegovy and Mounjaro ...

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP ... ahead of Wegovy with $19.4 billion, while the versions of the drug to treat diabetes – Mounjaro and Ozempic – will ...